(Total Views: 373)
Posted On: 03/29/2018 10:47:43 PM
Post# of 72433
IMO the results from the renal cancer combo work (not sure if it was a trial or just a test or something else) a number of years ago with another cancer treatment, those results showing the 1st and only time any reduction in tumor size for renal cancer was seen, pretty well established that K is going to work quite well for efficacy.
I realize it is a scant bit of evidence, but just like we have seen w/ B, every time we test K (as in the recent Ovarian trial) it works exactly as was seen in the pre-clinical and if the pre-clinical gave Dr. Menon the belief in K that he has than the odds that it is going to become the cancer killer he envisioned has a pretty good chance of occurring IMO. If i remember right, the Italian connection trial was showing positive results before they had to shut it down and I thought we heard of some positive efficacy in the P1 trial (can't guarantee if my memory is entirely accurate on this point).
As a last remark, since we showed the effectiveness of K in the p53 pathway as BP was hoping to see in the K-OC trial, I believe that pretty much indicates it would also have shown efficacy in reducing tumors if the full trial had been run.
I realize it is a scant bit of evidence, but just like we have seen w/ B, every time we test K (as in the recent Ovarian trial) it works exactly as was seen in the pre-clinical and if the pre-clinical gave Dr. Menon the belief in K that he has than the odds that it is going to become the cancer killer he envisioned has a pretty good chance of occurring IMO. If i remember right, the Italian connection trial was showing positive results before they had to shut it down and I thought we heard of some positive efficacy in the P1 trial (can't guarantee if my memory is entirely accurate on this point).
As a last remark, since we showed the effectiveness of K in the p53 pathway as BP was hoping to see in the K-OC trial, I believe that pretty much indicates it would also have shown efficacy in reducing tumors if the full trial had been run.
(1)
(0)